Portal de Periódicos da CAPES

CURRENT METHODS OF ASSESSING AND TREATING CARCINOMA IN SITU OF THE BLADDER WITH OR WITHOUT INVOLVEMENT OF THE PROSTATIC URETHRA

1995; Wiley; Volume: 2; Issue: s2 Linguagem: Inglês

10.1111/j.1442-2042.1995.tb00475.x

1442-2042

K. H. Kurth, P F Schellhammer, E Okajima, A. Akdaş, G. Jakse, HW Hen, F Calais da Silva, S Fukushima, Tadao Nagayama,

Urinary and Genital Oncology Studies

International Journal of UrologyVolume 2, Issue s2 p. 8-22 Free Access CURRENT METHODS OF ASSESSING AND TREATING CARCINOMA IN SITU OF THE BLADDER WITH OR WITHOUT INVOLVEMENT OF THE PROSTATIC URETHRA KH Kurth (c), Corresponding Author KH Kurth (c)AMC Department of Urolgy, Meiberdreef 9, 1105 AZ Amsterdam, The Netherlands. Phone: 31 (20) 566–3775 Fax: 31 (20) 691–1389Search for more papers by this authorPF Schellhammer (cc), PF Schellhammer (cc)Search for more papers by this authorE. Okajima (cc), E. Okajima (cc)Search for more papers by this authorA. Akdas, A. AkdasSearch for more papers by this authorG. Jakse, G. JakseSearch for more papers by this authorHW Hen, HW HenSearch for more papers by this authorF Calais da Silva, F Calais da SilvaSearch for more papers by this authorS. Fukushima, S. FukushimaSearch for more papers by this authorT. Nagayama, T. NagayamaSearch for more papers by this author KH Kurth (c), Corresponding Author KH Kurth (c)AMC Department of Urolgy, Meiberdreef 9, 1105 AZ Amsterdam, The Netherlands. Phone: 31 (20) 566–3775 Fax: 31 (20) 691–1389Search for more papers by this authorPF Schellhammer (cc), PF Schellhammer (cc)Search for more papers by this authorE. Okajima (cc), E. Okajima (cc)Search for more papers by this authorA. Akdas, A. AkdasSearch for more papers by this authorG. Jakse, G. JakseSearch for more papers by this authorHW Hen, HW HenSearch for more papers by this authorF Calais da Silva, F Calais da SilvaSearch for more papers by this authorS. Fukushima, S. FukushimaSearch for more papers by this authorT. Nagayama, T. NagayamaSearch for more papers by this author First published: June 1995 https://doi.org/10.1111/j.1442-2042.1995.tb00475.xCitations: 28AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat REFERENCES 1 Utz DC, Farrow GM. Carcinoma in situ in the urinary tract. Urol Clin North Am 1984; 11: 735. 2 Friedell G., Kotake T., Barlebo H., Jakse G., Fukushima S., Melamed M., Cohen S., Farrow G., Kakizoe T., Vahlensieck W. Transitional cell carcinoma in situ. In: T. Niijima, Y. Aso, W. Koontz, G. Prout, L. Denis (eds) Consensus Development in Clinical Bladder Cancer Research. Proceedings of the Second and Third International Consensus Development Symposia, 1993; 55– 64. 3 Weinstein RS, Miller AW III, Pauli BU. Carcinoma in situ. Comments on the pathobiology of a paradox. Urol Clin North Am 1980; 7: 523. 4 Farrow GM, Barlebo H., Enjoji M., Chisholm G., Friedell GH, Jakse G., Kakizoe T., Koss LG, Kotake T., Vahlensieck W. Transitional cell carcinoma in situ. In: Developments in Bladder Cancer. Progr Clin Biol Res. New York : Alan R Liss, 1986; ( 221) 85– 96. 5 Murphy WM, Soloway MS. Urothelial dysplasia. J Urol 1982; 127: 849. 6 Wolf H., Hojgaard K. Urothelial dysplasia in random mucosal biopsies from patients with bladder tumours. Scand J Urol Nephrol 1980; 14: 37. 7 Wolf H., Hojgaard K. Urothelial dysplasia concomitant with bladder tumors as a determinant factor for future new occurrences. Lancet 1983; 16: 134. 8 Farrow GM, Utz DC, Rife CC, Greene IF. Clinical observations on 69 cases of in situ carcinoma of the urinary bladder. Cancer Res 1977; 37: 2794. 9 Lamm DL. Carcinoma in situ. Urol Clin North Am 1992; 19: 499. 10 Utz DC, Farrow GM. Management of the carcinoma in situ of the bladder: a case for the surgical management. Urol Clin North Am 1980; 7: 533. 11 Soloway MS. Intravesical and systemic chemotherapy in the management of superficial bladder cancer. Urol Clin North Am 1984; 11: 623. 12 Wood DP Jr, Montie JE, Pontes JE, Medendorp S., Levin HS. Transitional cell carcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. J Urol 1989; 141: 346. 13 Schellhammer PF, Bean MA, Whitmore WF Jr. Prostatic involvement by transitional cell carcinoma: pathogenesis, patterns and prognosis. J Urol 1977; 118: 399. 14 Matzkin H., Soloway MS. Transitional cell carcinoma of the prostate: diagnosis, strategy and management. In: MS Soloway, DF Paulson (eds) Problems in Urology (vol. 6 No. 3). Philadelphia : JB Lippincott, 1992; 554– 563. 15 Sawczuk I., Tannenbaum M., Olsson CA, de Vere White RW. Primary transitional cell carcinoma of prostatic periurethral ducts. Urology 1985; 25: 339. 16 Zincke H., Utz DCH, Farrow GM. Review of Mayo Clinic experience with carcinoma in situ. Urology 1985; 26(suppl): 39. 17 Seemayer TA, Knaack J., Thelmo WL, Wang NS, Ahmad MN. Further observations on carcinoma in situ of the urinary bladder: silent but extensive intraprostatic involvement. Cancer 1975; 36: 514. 18 Prout GR Jr, Griffin PP, Daly JJ, Heney NM. Carcinoma in situ of the urinary bladder with and without associated vesical neoplasms. Cancer 1983; 52: 524. 19 Ro JY, Staerkel GA, Ayala AG. Cytologic and histologic features of superficial bladder cancer. Urol Clin North Am 1992; 19: 435. 20 Melicow MM, Hollowell JW. Intra–urothelial cancer: carcinoma in situ, Bowen's disease of the urinary system: discussion of thirty cases. J Urol 1952; 68: 763. 21 Ortega LG, Whitmore WF Jr, Murphy AI. In situ carcinoma of the prostate with intraepithelial extension into the urethra and bladder: a Paget's disease of the urethra and bladder. Cancer 1953; 6: 898. 22 Franks LM, Chesterman FC. Intra–epithelial carcinoma of prostatic urethra, peri–urethral glands and prostatic ducts: Bowen's disease of urinary epithelium. Br J Cancer 1956; 10: 223. 23 Johnson DE, Hogan JM, Ayala AG. Transitional cell carcinoma of the prostate: a clinical morphological study. Cancer 1972; 29: 287. 24 Mahadevia PS, Koss LG, Tar IJ. Prostatic involvement in bladder cancer: prostate mapping in twenty cystoprostectomy specimens. Cancer 1986; 58: 2096. 25 Schellhammer PF, Whitmore WF Jr. Transitional cell carcinoma of the urethra in men having cystectomy for bladder cancer. J Urol 1976; 115: 56. 26 Tomaszewski JE, Korat OC, LiVolsi VA, Connor AM, Wein A. Paget's disease of the urethral meatus following transitional cell carcinoma of the bladder. J Urol 1986; 135: 368. 27 Ro JY, Ayala AG, El–Naggar A., Wishnow I. Seminal vesicle involvement by in situ and invasive transitional cell carcinoma of the bladder. Am J Surg Pathol 1987; 11: 951. 28 Kurth KH, Denis L., Ten Kate FJW, Sylvester R., de Pauw M., Bouffioux CH, Debruyne FMJ, Pavone–Macaluso M., Oosterlinc W. Prognostic factors in superficial bladder tumors. In: MS Soloway, DF Paulson (eds) Problems in Urology (vol. 6 No. 3). Philadelphia : JB Lippincott, 1992; 471– 483. 29 Jakse G. Personal Communication, 1993. 30 Richards B., Parmar MKB, Anderson CK, Ansell ID, Grigor K., Hall RR, Morley AR, Mostofi FK, Risdon RA, Uscinska BM, the MRC Superficial Bladder Cancer Subgroup. Interpretation of biopsies of "normal" urothelium in patients with superficial cancer. Br J Urol 1991; 67: 369. 31 Melamed M., Barlebo H., Nagayama T., de Voogt H., Farrow G., Farsund T., Felderhof J., Fukushima S., Highman W., Koss L., Pressman N., Reiss, E., Tanke H., Tazaki H., Tribukait B. The role of cytology in the diagnosis, detection and follow–up of bladder cancer. In: T. Niijima, Y. Aso, W. Koontz, G. Prout, L. Denis (eds) Consensus Development in Clinical Bladder Cancer Research. Proceedings of the Second and Third International Consensus Development Symposia, 1993; 65– 77. 32 Herr HW. Carcinoma in situ of the bladder. Sem Urol 1983; 1: 15. 33 Badalament RA, Kimmel M., Gay H., Cibas CS, Whitmore WF Jr, Herr HW, Fair WR, Melamed MR. The sensitivity of flow cytometry compared with conventional cytology in the detection of superficial bladder carcinoma. Cancer 1987; 59: 2078. 34 Matzkin H., Moinuddin SM, Soloway MS. Value of urine cytology versus bladder washing in bladder cancer. Urology 1992; 39: 201. 35 Murphy WM, Crabtree WN, Jukkola AF, Soloway MS. The diagnostic value of urine versus bladder washing in patients with bladder cancer. J Urol 1981; 126: 320. 36 Soloway MS. Editorial comment. J Urol 1993; 149: 459. 37 Riddle PR, Chisholm GD, Trott PA, Pugh RCB. Flat carcinoma in situ of the bladder. Br J Urol 1976; 47: 829. 38 Koss LG, Melamed MR, Kelly RE. Further cytologic and histologic studies of bladder lesions in workers exposed to para–aminodiphenyl: progress report. J Natl Cancer Inst 1969; 43: 233. 39 Fukui I., Yokokawa M., Sekine H., Yamada T., Hosoda K., Ishiwata D., Oka K., Sarada T., Tohma T., Yamada T., Oshima H. Carcinoma in situ of the urinary bladder: effect of associated neoplastic lesions on clinical course and treatment. Cancer 1987; 59: 164. 40 Prout GR Jr, Griffin PP, Daly JJ. The outcome of conservative treatment of carcinoma in situ of the bladder. J Urol 1987; 138: 76. 41 Herr HW, Pinsky CM, Whitmore WF Jr, Sogani PC, Oettgen HF, Melamed MR. Long term effect of intravesical bacillus Calmette–Guerin on flat carcinoma in situ of the bladder. J Urol 1986; 135: 265. 42 de Boer EC, De Jong WH, Van der Meijden APM, Steerenberg PA, Witjes F., Vegt PDJ, Debruyne FMJ, Ruitenberg EJ. Leukocytes in urine after intravesical BCG treatment for superficial bladder cancer: a flow cytofluorometric analysis. Urol Res 1991; 19: 45. 43 de Boer EC, De Jong WH, Van der Meijden APM, Steerenberg PA, Witjes JA, Vegt PDJ, Debruyne FMJ, Ruitenberg EJ. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette–Guerin. Cancer Immunol Immunother 1991; 33: 411. 44 de Boer EC, de Jong WH, Steerenberg PA, Aarden LA, Tetteroo E., De Groot ER, Van der Meijden APM, Vegt PDJ, Debruyne FMJ, Ruitenberg EJ. Induction of urinary interleukin–1 (IL–1), IL–2, IL–6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette–Guerin in superficial bladder cancer. Cancer Immunol Immunother 1992; 34: 306. 45 Van der Meijden APM, de Jong WH, Steerenberg PA, Walvoort HC, de Boer EC, Debruyne FMJ, Ruitenberg EJ. Intravesical BCG administration in the guinea pig. A histomorphological study. Virchows Archiv B Cell Pathol 1988; 55: 207. 46 Ratliff TL. Mechanisms of action of BCG in superficial bladder cancer. In: EORTC Genitourinary Group Monograph 11: Recent progress in bladder and kidney cancer. Progr Clin Biol Res. New York : Wiley–Liss, 1992; 378: 103. 47 Prescott S., James K., Hargreave TB, Chisholm GD, Smyth JF. Radioimmunoassay detection of interferon–gamma in urine after intravesical Evans BCG therapy. J Urol 1990; 144: 1248. 48 Bohle A., Nowc CH, Ulmer AJ, Musehold J., Gerdes J., Hofstetter AG. Elevations of cytokines interleukin–1, interleukin–2, and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette–Guerin immunotherapy. J Urol 1990; 144: 59. 49 Morales A., Eidinger D., Bruce AW. Intracavitary bacillus Calmette–Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116: 180. 50 Torti FM, Shortliffe LD, Williams RD, Pitts WC, Kempson RL, Ross IC, Palmer J., Meyers F., Ferrari M., Hannigan J., Spiegel R., McWhirter K., Freiha F. Alpha–interferon in superficial bladder cancer: a Northern California Oncology Group study. J Clin Oncol 1988; 6: 476. 51 Glashan RW. A randomized controlled study of intravesical a–2b–interferon in carcinoma in situ of the bladder. J Urol 1990; 144: 658. 52 Maricic Z., Nola P., Ikic D., Smudj K., Oresic V., Knezevic M., Rode B., Jusic D., Soos E. Human leukocyte interferon in therapy of patients with urinary bladder papillomatosis, breast cancer and melanoma. J Cancer Res Clin Oncol 1981; 101– 317. 53 da Calais Silva F., and members of Portuguese Genitourinary Group: Interferon alpha 2b 60 millions vs. 100 millions in intravesical prophylaxis of superficial bladder cancer. J Urol 1993; 149(suppl): 282A, 274. 54 Cockett ATK, Davis RS, Cos LR, Wheeless LL Jr. Bacillus Calmette–Guerin and Interleukin–2 for treatment of superficial bladder cancer. J Urol 1991; 146: 766. 55 Huland E., Huland H. Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res 1989; 49: 5469. 56 Pizza G., Severini G., Menniti D., de Vinci C., Corrado F. Tumour regression after intralesional injection of interleukin 2 (IL–2) in bladder cancer. Preliminary report. Int J Cancer 1984; 34: 359. 57 Raica, M. Effects of intravesical Corynebacterium parvum on recurrences of superficial tumors of the urinary bladder. Anti–Cancer Drugs 1992; 3: 39. 58 Jurincic CD, Engelmann U., Gasch J., Klippel KF. Immunotherapy in bladder cancer with Keyhole–Limpet Hemocyanin: a randomized study. J Urol 1988; 139: 723. 59 Flamm J., Bucher A. Adjuvant topical chemotherapy versus immunotherapy in primary superficial transitional cell carcinoma of the bladder. Br J Urol 1991; 67: 70. 60 Ratliff TL, Gillan D., Catalona WJ. Requirement of a thymus dependent immune response for BCG–medi–ated antitumor activity. J Urol 1987; 137: 155. 61 Zbar B., Bernstein ID, Bartlett GI, Hanna MG Jr, Rapp HI. Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph, node metastases after intralesional injection of living Mycobacterium. J Natl Cancer Inst 1972; 49: 119. 62 Schamhart DHJ, Bevers R., Vos PN, Kurth KH, de Boer EC, Steerenberg PA. Effects of modulation of mycobacterial adherence to the bladder wall and BCG treatment. J Urol 1992; 147(suppl.): 274A, 243. 63 Torrence RJ, Kavoussi LR, Catalona WJ, Ratliff TL. Prognostic factors in patients treated with intravesical bacillus Calmette–Guerin for superficial bladder cancer. J Urol 1988; 139: 94. 64 Schamhart DHJ, Kurth KH, De Reijke ThM, Vleeming R. BCG treatment and the importance of an inflammatory response. Urol Res 1992; 20: 199. 65 Haaff EO, Dresner SM, Ratliff TL, Catalona WJ. Two courses of intravesical bacillus Calmette–Guerin for transitional cell carcinoma of the bladder. J Urol 1986; 136: 820. 66 Harland SJ, Charig CR, Highman W., Parkinson MC, Riddle PR. Outcome in carcinoma in situ of bladder treated with intravesical bacillus Calmette–Guerin. Br J Urol 1992; 70: 271. 67 Jakse, G. Bacillus Calmette–Guerin (BCG) in the treatment of carcinoma in situ of the urinary bladder. Akt Urol 1993; 24(suppl): 22– 27. 68 Kavoussi LR, Torrence RJ, Gillen DP, Hudson MA. Haaff EO, Dresner SM, Ratliff TL, Catalona WJ. Results of 6 weekly intravesical bacillus Calmette–Guerin instillations on the treatment of superficial bladder tumors. J Urol 1988; 139: 935. 69 Lamm DL, Crawford ED. Blumenstein B., Grissman JD, Montie J., Gottesman J., Lowe B., Sarosdy MF, Bohl RD, Weems WL, Grossman HB, Smith JA, Beck TM. Leimert J., Coltman CA. Maintenance BCG immunotherapy of superficial bladder cancer: a randomized prospective Southwest Oncology Group study. J Urol 1992; 147(suppl): 274A, 242. 70 Kelley DR, Ratliff TL, Catalona WJ, Shapiro A., Lage JM, Bauer WC, Haaff EO, Dresner SM. Intravesical bacillus Calmette–Guerin therapy for superficial bladder cancer: effect of bacillus Calmette–Guerin viability on treatment results. J Urol 1985; 134: 48. 71 Mukherjee A., Persad R., Smith JB. Intravesical BCG treatment for superficial bladder cancer: long–term results using two different strains of BCG. Br J Urol 1992; 69: 147. 72 Witjes JA, Van der Meijden APM, Witjes WPJ, Doesburg W., Schaafsma HE, Debruyne FMJ. A randomised prospective study comparing intravesical instillations of Mitomycin–C, BCG–Tice, and BCG–RIVM in pTa–pTl tumors and primary carcinoma in situ of the urinary bladder. Intravesical instillations in superficial bladder cancer. Eur J Cancer 1993; 29: 1672– 1676. 73 Lamm DL, DeHaven JI, Shriver J., Sarosdy MF. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette–Guerin versus intravesical bacillus Calmette–Guerin in superficial bladder cancer. J Urol 1991; 145: 738. 74 Witjes JA, Fransen MPH, Van der Meijden APM, Doesburg WH, Debruyne FMJ. The use of maintenance intravesical BCG, with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long term follow up of a randomised phase 2 study. Urol Int 1993; 51: 67– 72. 75 Lamm DL, Reichert DF, Harris SC, Lucio RM. Immunotherapy of murine transitional cell carcinoma. J Urol 1982; 128: 1104. 76 Dresner SM, Ratliff TL, Kelley DR, Catalona, WJ. Determination of optimal dose and strain of BCG for inhibition of intravesical mouse bladder tumor growth. J Urol 1985; 133: 267A, 616. 77 Merz VW, Marth D., Zingg EJ, Studer UE. Analysis of early failures after intravesical instillation therapy with bacillus Calmette–Guerin for carcinoma in situ of the bladder. J Urol 1993; 149(suppl): 283A, 27. 78 Catalona WJ, Hudson MA, Gillen DP, Andriole GL, Ratliff TL. Risks and benefits of repeated courses of intravesical bacillus Calmette–Guerin therapy for superficial bladder cancer. J Urol 1987; 37: 220. 79 Brosman SA. Indications for BCG use in carcinoma in situ. Urology 1991; 37(suppl 5): 12. 80 Herr HW, Laudone VP, Badalament RA, Oettgen HF, Sogani PC, Freedman BD, Melamed MR, Whitmore WF Jr. Bacillus Calmette–Guerin therapy alters the progression of superficial bladder cancer. J Clin Oncol 1988; 6: 1450. 81 Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P., Grossmann HB, Stanisic TH, Smith JA Jr, Sullivan J., Sarosdy MF, Crissman JD, Coltman CA. A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette–Guerin for transitional– cell carcinoma of the bladder. N Engl J Med 1991; 325: 1205. 82 Schellhammer PF, Lagoda LE, Moriatry RP. Intravesical bacillus Calmette–Guerin for treatment of superficial transitional cell carcinoma of the prostatic urethra in association with carcinoma of the bladder. J Urol 1995; 153: 53– 56. 83 Chibber PJ, Mclntyre MA, Hindmarsh JR, Hargreave TB, Newsam JE, Chisholm CD. Transitional cell carcinoma involving the prostate. Br J Urol 1981; 53: 605. 84 Bretton PR, Herr HW, Whitmore WF Jr, Badalament RA, Kimmel M., Provet J., Oettgen HF, Melamed MR, Fair WR. Intravesical bacillus Calmette–Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra. J Urol 1989; 141: 853. 85 Lockhart JL, Chaikin L., Bondhus MJ, Politano VA. Prostatic recurrences in the management of superficial bladder tumors. J Urol 1983; 130: 256. 86 Hardeman SW, Soloway MS. Urethral recurrence following radical cystectomy. J Urol 1990; 144: 666. 87 Sarosdy M. High–dose versus low–dose intravesical interferon–alpha 2b in the treatment of carcinoma in situ: a randomized, controlled study. Anticancer drugs 1992; 3(suppl 1): 13. 88 Jakse G., Hofstadter F., Marberger H. Topical doxorubicin hydrochloride therapy for carcinoma in situ of the bladder: a follow–up. J Urol 1984; 131: 41. 89 Prout GR Jr, Koontz WW Jr, Coombs LJ, Hawkins IR, Friedell GH. Long term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. J Urol 1983; 130: 677. 90 Strieker PD, Grant ABF, Hosken BM, Taylor JS. Topical mitomycin C therapy for carcinoma in situ of the bladder: a follow–up. J Urol 1990; 143: 34. 91 Kurth KH, Schroder FH, Tunn U., Ay R., Pavone–Macaluso M., Debruyne F., de Pauw M., Dalesio O., Ten Kate F., and members of the European Organization for Research on Treatment of Cancer, Genitourinary Tract Cancer Cooperative Group: Adjuvant chemotherapy of superficial transitional cell carcinoma of the bladder. J Urol 1984; 132: 258. 92 Kurth KH, Vijgh WJF, Ten Kate FWJ, Bogdanowicz JF, Carpentier PJ, van Reyswoud I. Phase 1/2 study of intravesical epirubicin in patients with carcinoma in situ of the bladder. J Urol 1991; 146: 1508. 93 Jakse G., Putz A., Feichtinger J. Cystectomy: the treatment of choice in patients with carcinoma in situ of the urinary bladder Eur J Surg Oncol 1989; 15: 211. 94 Klein EA, Rogatko A., Herr HW. Management of local bacillus Calmette–Guerin failures in superficial bladder cancer. J Urol 1992; 147: 601. 95 Coplen DE, Marcus MD, Myers JA, Ratliff TL, Catalona WJ. Long–term followup of patients treated with 1 or 2, 6–week courses of intravesical bacillus Calmette–Guerin: analysis of possible predictors of response free of tumor. J Urol 1990; 144: 652. 96 Droller MJ, Walsh PC. Intensive intravesical chemotherapy in the treatment of flat carcinoma in situ: is it safe J Urol 1985; 134: 1115. 97 Whitmore WF Jr. Management of bladder cancer. Curr Probl Cancer 1979; 4: 1. 98 Montie JE, Wood DP Jr, Medendorp S., Levin HS, Pontes JE. The significance and management of transitional cell carcinoma of the prostate. Sem Urol 1990; 8: 262. 99 Gomer GJ. Yearly Review: Preclinical examination of first and second generation photosensitizers used in photodynamic therapy. Photochem Photobiol 1991; 54: 1093. 100 Kelly JF, Snell ME, Berenbaum MC. Photodynamic destruction of human bladder carcinoma. Br J Cancer 1975; 31: 237. 101 Williams RD, Runge TC. Photodynamic therapy of human bladder cancer cells in vitro correlated with cellular fluorescent levels of Photofrin II. Photochem Photobiol 1987; 46: 733. 102 Tsuchiya A., Obara N., Miwa M., Ohi T., Kato H., Hayata Y. Hematoporphyrin derivative and laser photoradiation in the diagnosis and treatment of bladder cancer. J Urol 1983; 130: 79. 103 Hisazumi H., Misaki T., Miyoshi N. Photoradiation therapy of bladder tumors. J Urol 1983; 130: 685. 104 Prout GR, Lin CW, Benson R., Nseyo UO, Daly JJ, Griffin PP, Kinsey J., Tian M., Lao Y., Mian Y., Chen X., Ren F., Qiao S. Photodynamic therapy with Hematoporphyrin derivative in the treatment of superficial transitional cell carcinoma of the bladder. N Engl J Med 1987; 317: 1251. 105 Marcus SL, Dugan MH. Global status of clinical photodynamic therapy. Lasers Surg Med 1992; 12: 318. 106 D'Hallewin MA, Baert L., Marijnissen JPA, Star WM. Whole bladder wall photodynamic therapy with in situ light dosimetry for carcinoma in situ of the bladder. J Urol 1992; 148: 1152. 107 Jocham D., Beer M., Baumgartner R., Staehler G., Unsold E. Long–term experience with integral photodynamic therapy of Tis bladder carcinoma. Ciba Found Symp 1989; 146: 198. 108 Manyak MJ. Photodynamic Therapy: Principles and urological applications. Sem Urol 1991; 9: 192. 109 Miller EB, Eure GR, Schellhammer PF. Upper tract transitional cell carcinoma in patients treated with BCG. J Urol 1992; 147(suppl): 272A, 236. 110 Schwalb DM, Herr HW, Sogani PC, Russo P., Sheinfeld J., Fair WR. Upper tract disease following intravesical BCG for superficial bladder cancer: five year follow–up. J Urol 1992; 147(suppl): 273A, 237. 111 Herr HW, Wartinger DD, Fair WR, Oettgen HF. Bacillus Calmette–Guerin therapy for superficial bladder cancer. a 10–year followup. J Urol 1992; 147: 1020. 112 Herr HW. Unpublished data, 1993. 113 Schwalb DM, Herr HW. Positive urinary cytology following a complete response to BCG therapy: pattern recurrence. J Urol 1994; 152: 382– 387. 114 Herr HW. Durable response of a carcinoma in situ of the renal pelvis to topical bacillus Calmette–Guerin. J Urol 1985; 134: 531. 115 Sharpe JR, Duffy G., Chin JL. Intrarenal bacillus Calmette–Guerin therapy for upper urinary tract carcinoma in situ. J Urol 1993; 149: 457. 116 Huffman JL, Bagley DH, Lyon ES, Morse MJ, Herr HW, Whitmore WF Jr. Endoscopic diagnosis and treatment of upper tract urothelial tumors: a preliminary report. Cancer 1985; 55: 1422. 117 Herr HW, Whitmore WF Jr. Ureteral carcinoma in situ after successful intravesical therapy for superficial bladder tumors: incidence, possible pathogenesis and management. J Urol 1987; 138: 292. 118 Gerber GS, Lyon ES. Endo–urological management of upper tract urothelial tumors. J Urol 1993; 150: 2. 119 Schwalb DM, Herr HW. The management of clinically unconfirmed positive urinary cytology. J Urol 1993; 150: 1751– 1756. 120 Tyrkus M., Powell I., Fakr W. Cytogenetic studies of carcinoma in situ of the bladder: prognostic implications. J Urol 1992; 148: 44. 121 Sanchez–Fernandez de Sevilla MC, Morell–Quadreny L, Gil–Salom M, Perez–Bacete M, Llombart–Bosch A. Morphometric and immunohistochemical characterization of bladder carcinoma in situ and its preneoplastic lesions. Eur Urol 1992; 21(suppl): 5. 122 Fujimoto K., Yamada Y., Okajima E., Kakizoe T., Sasaki H., Sugimura T., Terada M. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 1992; 52: 1393. 123 Spruck CH, Esrig D., Gonzalez M., Ohneseit PF, Steven K., Horn T., Herman GR, Cote RJ, Jones PA. p53 mutation: an early event in the formation of transitional cell carcinoma in situ. J Urol 1993; 149 (suppl): 237A, 95. 124 Sarkis AS, Dalbagni G., Cordon–Cardo C., Melamed J., Zhang ZF, Sheinfeld J., Fair WR, Herr HW, Reuter VE. Association of pS3 nuclear over expression and tumor progression in carcinoma in situ. J Urol 1994; 152: 388. Citing Literature Volume2, Issues2June 1995Pages 8-22 ReferencesRelatedInformation